Study of F527 in Patients With Relapsed or Refractory Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-05-20
Target enrollment:
Participant gender:
Summary
This study is a non-randomized, open-label, phase I dose-finding and dose-expansion study to
evaluate the safety, tolerability, antitumor efficacy, PK and immunogen of F527 in patients
with relapsed or refractory lymphoma sexual characteristics.